Microsoft Dragon Copilot vs Suki (2026)
Both products stopped being scribes some time ago, and the question is which expansion you want and how much you can see of it. Suki adds a voice command layer over the record: a clinician can order, navigate, stage and query by speaking, and orders are staged for review rather than submitted. Dragon Copilot adds roles, evidence summaries and letters, and it publishes an account of where the models degrade. On the axes that describe how each system behaves, transparency, governance and evidence, Dragon Copilot is ahead and Suki publishes essentially nothing. On the axis that describes what the clinician can do inside the chart, Suki is ahead. Decide which failure you would rather manage: a command misheard at the order staging step, or a documentation product whose randomized efficiency result was not significant.
- It publishes how the system fails. Named limitations, a sub processor list, an explicit statement that models underperform on some accents and dialects, and honest maturity labelling of preview features. Suki publishes no model name, no accuracy figure and no governance artefact of any kind.
- Role based coverage for nurses and radiologists rather than one clinician assistant, plus multilingual multi party capture and generated referral and patient letters.
- If the estate is Microsoft, the contracting, identity and cloud relationship already exist. That is not a feature, but it is usually the reason a health system finishes this evaluation faster than it expected to.
- The voice command layer is the product and nothing else in this category matches it. A clinician can order medications, navigate the chart, stage orders and ask questions of the specific patient record by speaking, which requires write access rather than note insertion.
- Depth across record systems that competitors treat as second tier, with deep bidirectional integrations named across Epic, Oracle Health, athenahealth and MEDITECH, plus a developer platform that lets other healthcare software vendors embed the capability.
- The oversight ceiling is set in the design rather than in a disclaimer: voice commands stage orders for clinician review instead of submitting them, so a human decision sits between the model and any clinical action.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Microsoft Dragon Copilot and Suki are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Microsoft Dragon Copilot | Suki |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2025 | 2017 |
| Headquarters | Redmond, Washington, United States | Redwood City, California |
| Website | microsoft.com | suki.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Microsoft Dragon Copilot its top capability grade on several axes, including AI Centrality, Model Supply Chain Disclosure and FDA and Regulatory Status. Set against Suki, Microsoft Dragon Copilot grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Suki its top capability grade on AI Centrality and EHR and Interoperability Depth. Set against Microsoft Dragon Copilot, Suki does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Microsoft Dragon Copilot or Suki?
The AI Health Index grades Microsoft Dragon Copilot higher than Suki on every axis that separates them, several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Clinical and Operational Evidence. Suki does not grade higher on any scored axis.
Where do Microsoft Dragon Copilot and Suki differ most?
The widest separation the AI Health Index records between Microsoft Dragon Copilot and Suki is on Model Supply Chain Disclosure, where Microsoft Dragon Copilot grades A and Suki grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Microsoft Dragon Copilot and Suki grade the same?
The AI Health Index grades Microsoft Dragon Copilot and Suki the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Neither vendor publishes pricing, and Suki additionally offers no free tier and no free trial, so a clinician cannot test accuracy on their own notes before entering a sales process. Suki publishes no accuracy rate for command interpretation and no escalation behaviour for a misheard command, which is the disclosure this comparison most needs given that the command layer touches orders.
Dragon Copilot's efficiency result in the November 2025 NEJM AI randomized trial was 1.7 percent reduction in time in note and was not statistically significant; Suki has no controlled evaluation of any kind.